20230414_民生证券_医药行业证券研究报告:锦波生物国内首研重组人源化胶原蛋白创新引领功能蛋白智造_51页.pdf

返回 相关 举报
20230414_民生证券_医药行业证券研究报告:锦波生物国内首研重组人源化胶原蛋白创新引领功能蛋白智造_51页.pdf_第1页
第1页 / 共51页
20230414_民生证券_医药行业证券研究报告:锦波生物国内首研重组人源化胶原蛋白创新引领功能蛋白智造_51页.pdf_第2页
第2页 / 共51页
20230414_民生证券_医药行业证券研究报告:锦波生物国内首研重组人源化胶原蛋白创新引领功能蛋白智造_51页.pdf_第3页
第3页 / 共51页
20230414_民生证券_医药行业证券研究报告:锦波生物国内首研重组人源化胶原蛋白创新引领功能蛋白智造_51页.pdf_第4页
第4页 / 共51页
20230414_民生证券_医药行业证券研究报告:锦波生物国内首研重组人源化胶原蛋白创新引领功能蛋白智造_51页.pdf_第5页
第5页 / 共51页
亲,该文档总共51页,到这儿已超出免费预览范围,如果喜欢就下载吧!
资源描述
*2023 4 14*HPV III 2021 6 HPV 2021-2022 2.33 3.90+44.75%+67.15%0.57 1.09+79.62%+90.24%2022 3.34 104.98%85.60%1 2016-2019 CAGR 8%HPV 2020 3.32 2 HPV HPV 3 2025 130 2019-2025 CAGR 28%2025 328 82%2025 300 5 CAGR 29.1%50 5 CAGR 66%2025 10 2021-2025 CAGR 62%+1-2 3 HPV 2023 2 15 PCHi 3kDa micoreCol.A 4 1 XVDWwPnQmPrQpRtQqNpQqRaQcMaQmOmMoMpMlOqQrNeRrQnR9PoPnOvPtPpQMYoNvN*2C O N T E N T S 02 03 01 04 05*01.3*1.14 2008 2012 HPV 2014 2019 2021 III 2023 3 20082008 2012 HPV HPV()2014 2019()2021 2022 XVII 20233*1.25-1965 2012 1 2018 1 CEO 2018 10 2021 2 2018 12 2021 1 2020 5 2020 10 2019 1 2022 7 2021 11 2021 8 1968 2002 1 2003 3 2003 3 2013 3 2013 3 2016 12 2021 8 2021 8 1966 2014 2 2015 3 2015 3 2016 12 2016 12 1987 2012 7 2019 8 2019 10 2020 1 2021 8 1987 2008 9 2015 3 2015 3 2021 8 2020 6 2015 3 1971 2003 6 2009 1 2009 2 2016 10 2016 11 2017 2 2021 8*1.36 2023 3 2023 3 64.33%1.17%1.93%1.51%1.38%*1.47 HPV 1 III 2021 6 2 HPV HPV III III()()164.88 164.88 HPV HPV/HPV HPV*1.48 III 2021 6/III III 2mg 4mg 6mg 8mg 10mg/2g 3g 5g 10g 15g 20g 25g 30g 40g 50g 80g/III III 0.5g 1g 2g 3g 5g 10g 15g 20g 25g 30g 40g 50g 80g/2g 3g 5g 10g 20g 30g 40g 50g 80g 100g/*HPV 1.49 HPV HPV HPV-HPV HPV HPV HPV/HPV HPV HPV HPV HPV 1.5g 1.8g 2g 2.5g 3g 3.3g 5g 10g 20g 50g 100g/HPV HPV HPV HPV 2 3 5 10 15 20 25 30 40 50 80g/HPV*22 85.6%1.510 2021-2022 yoy/2021 2022 yoy yoy 16290.79 60.95%69.79%33392.24 104.98%85.60%HPV 5572.69 19.27%23.87%4670.25-16.19%11.97%1473.56 14.94%6.31%947.84-35.68%2.43%6.66-87.03%0.03%/2019 2018 2017-5990.00 42.23%5366.68 41.29%4,344.49 44.47%1866.99 13.19%1597.48 12.29%820.49 8.40%4,144.37 29.29%1216.79 9.36%1011.52 10.35%8.84 0.06%6,020.20 42.54%2,814.26 21.65%1,832.01 18.75%348.02 2.46%423.90 3.26%750.68 7.68%50.24 0.36%398.26 2.81%423.90 3.26%750.68 7.68%778.20 5.50%804.37 6.19%799.38 8.18%148.69 1.06%2346.32 18.05%717.68 7.35%816.17 5.77%1,242.28 9.56%1,324.40 13.56%1,743,06 12.32%4,392.97 33.80%2.841.46 29.09%14,151.52 100.00%12,997.81 100.00%9,768,61 100.00%2017-2019 1 2017-2019-40%-HPV 2 2021-2022 2021-2022 104.98%2022 85.60%2020-2022 42.74%/50.01%/71.41%HPV 98%10*1.611 2022 6 1 2 3 4 OBM ODM OBM 2022H1 OBM 86.3%38.5%47.8%2022 1-6 2021 2020 2019 OBM 13302.26 86.29%18123.24 77.66%12808.23 79.67%11824.31 83.56%164.88 5930.44 38.47%7814.98 33.49%5192.46 32.30%2503.74 17.69%4827.45 31.32%6361.69 27.26%4200.00 26.13%666.11 4.71%1102.98 7.16%1453.29 6.23%992.46 6.17%1837.62 12.99%7371.82 47.82%10308.26 44.17%7615.77 47.37%9320.57 65.86%ODM 2112.71 13.71%5213.80 22.34%3267.89 20.33%2327.21 16.44%15414.97 100%23337.04 100%16076.12 100%14151.52 100%*1.712 1 2 3)*1 2 42.55%2 1.5 3 1.2 1.813 20000.00 42.55%15000.00 31.91%12000.00 25.53%47000.00 100%42.55%31.91%25.53%*02.14*2.1 Hyaluronic Acid D-N-N-15g HA Mr HA Mr 200 500-1000 CD44 15*2.1 1977 1981-2000 1981 Zyderm FDA 2000-2015 2015 2017-2021 Vs 2017 2018 2019 2020 2021 25 34 43 55 78 19 31 61 81 115 114 139 164 172 217 2017 2018 2019 2020 2021 9 16 32 44 73 16 21 26 28 37 16*2.1/95%17*+2.1 2021.3.15 2021.4.15 2022.3.24 2022 4 1 2022.4.24/NMPA NMPA 18*2016-2019 CAGR 8%2016-2019 CAGR 8%Grand View Research 2020 156.84 2016-2020 CAGR 5.5%2025 203.64 2019 9.8 6.4%2016-2019 CAGR 8%2.119 0%20%40%60%05001000150020002017 2018 2019 2020 2021 2022E 2023E 2024E 2025E 2026E 2027E*DNA 2021 108 2017-2021 CAGR 63.0%2022 182 46.6%2.120 15.9%20.2%26.3%31.4%37.7%46.6%0%10%20%30%40%50%0501001502002017 2018 2019 2020 2021 2022E*2.1 CR5 67.5%CR5 25%2025 328 82%306 1 21.0%2 12.4%3 11.9%4 11.6%5 10.6%67.5%32.5%2021 Z 2017 2021 2017 2018 2019 2020 2021 8 13 20 29 46 8 10 11 12 16 16 23 31 41 62 25 34 43 55 78 92 107 122 137 168 133 164 196 233 308 2022E 2023E 2024E 2025E 2026E 2027E 72 112 174 269 416 645 22 30 41 59 87 130 94 142 215 328 503 775 109 154 217 306 434 617 208 259 328 420 547 726 411 555 760 1054 1484 2118 2022 2027 21*2.1 2021 28%45%1-3 1-2.5 1.5-3 8-30/14-40/35-40/14-40/2017 2018 2019 2020 2021 13.43%16.84%22.22%24.18%28.29%5.97%8.42%12.5%14.84%18.6%28.36%32.63%42.36%44.51%44.57%2021 CR5 26.5%23 9%1 10.1%2 9.0%3 F 2.8%4 2.6%5 H 2.0%26.5%73.5%2021 22*2.1 1 2025 300 5 CAGR 29.1%50 5 CAGR 66%2 2025 10 2021-2025 CAGR 62%2025 10 3 2025 50 2020 2020-2025 2025 E 912 24.50%2726.8 1000 3-4%1200 91.2 29.11%327.21 1%-5%9.12-136.34/5300-4%4300 4.83 64.7%58.62021 2021-2025 2025 E 28.7 20.30%60.1+3.50%-7%+1.00 4.21+2.0%4%0.020 0.168/7500-3.5%6500 1.51 62%10.94 1 3 PLLA 2021-2025 CAGR 75.9%23*1 2020 1520 200-450 1/7 1/3 34%2025 300 5 CAGR 29.1%50 III 2.5ml Q-Med 2 2025 10 2021-2025 CAGR 62%2.124*2.125/III 2.5ml Q-Med NMPA 49802330 3-6 3-6 2.539801500 1 9 Q-Med AB TM 6800 12-15 5300 3 NMPA I III 12800 3-6 I 13800 9 III 6800 1-3 L-2580 3-4*HPV 2020 3.32 HPV HPV IARC 99%HPV 2020 6 7-HPV 2020 HPV 22.79 3.32 2.126 HPV 1.21.712.723.99 4.433.329.811.2612.917.4719.4319.460510152025302015 2016 2017 2018 2019 2020HPV*HPV HPV HPV HPV 50%1 2b 2b 2b 2b 2020 HPV 2b 20.61%2 HPV 2020 HPV 29.76%3 HPV-HPV HPV 2020 HPV HPV 14.58%2.127*SARS-CoV-2HR17 EKI EK1 2.128 S2 HR1/HR2 S1 RBD/NTD/*2020 330 8.1%7.6%2027 550 60 2.129*03.30*-36 22 3 4 3.131*3.232 10 8 5 7*3.233:3D*3.234-HPV HPV HPV*BSL-2-29 7 1 ProteinDataBank PDB I II III V XVII 5 1 V XVII 2019-2022H1 1382.31 2376.99 2906.93 2102.47 8.86%14.74%12.45%13.64%2021/9.25%/1.6%/2.81%3.235 2023 3 17 2013ZX10001006004 2018ZX10301-403-005-002 2021LP01469 EK1 2021 9 9*HPV HPV EK1 2021 9 9 III III 2021 6 III 3.336 100%100%164.88 PDB 183%183%*2023 2 15 PCHi 3kDa micoreCol.A micoreCol.1.83 3kDa 164.88 4 33%12 86%micoreCol.28 3.337*1 2 3.438/III III I I EK1 EK1 HCoV*04.39*22+67.15%3.90 4.140 2019-2022 yoy iFind 2021-2022 2021-2022 2022+67.15%3.90 2021 6 2021-2022 2022+67.15%3.9 2021-2022 2022 3.34 85.60%2021 15.79 PCT 21.77%3.42%44.75%67.15%0%20%40%60%80%010000200003000040000500002019 2020 2021 2022 yoy0%20%40%60%80%100%2021 2022 HPV*2019-2022 80%2019-2022 84.69%/80.01%/82.29%/85.44%III 2019-2022 80.66%/78.33%/81.69%/86.05%HPV 41 2019-2022 2019-2022 4.2 50%70%90%2019 2020 2021 2022 HPV 84.69%80.01%82.29%85.44%76%78%80%82%84%86%2019 2020 2021 2022*2022 26.9%2020 25%2022 1.05 2021 87.52%2021 2021 48.05%27.22%4.342 2018-2022 2018-2020 0%20%40%60%80%100%2018 2019 2020 18.9%27.6%23.3%24.0%26.9%0%5%10%15%20%25%30%0200040006000800010000120002018 2019 2020 2021 2022%iFind*2022 15.06%43 2018-2022 2018-2020 4.3 2022 15.06%17.27%8.86%19.49%15.35%15.06%8%10%12%14%16%18%20%22%010002000300040002018 2019 2020 2021 2022%0%20%40%60%80%100%2018 2019 2020 iFind*1 2022 2021 7.69%2 2021 2020 3.74%1507.65 44 2018-2022 2018-2020 4.3 22 11.42%17.27%17.85%20.41%19.11%11.42%0%5%10%15%20%25%0100020003000400050002018 2019 2020 2021 2022%0%20%40%60%80%100%2018 2019 2020 iFind*2022 90.24%1.09 2020 2021 2020-2022 0.32/0.57/1.09 2021-2022 79.62%90.24%2020-2022 19.81%/24.58%/27.98%4.445 2019-2022 yoy 2019-2022 2022 27.98%3.28%-29.42%79.62%90.24%-60%-30%0%30%60%90%120%0200040006000800010000120002019 2020 2021 2022 yoy29.03%19.81%24.58%27.98%15%20%25%30%2019 2020 2021 2022 iFind*05.46*05 47 1 2 3*THANKS 8 1 5F 200120 28 A 19 100005 6001 32 05 518026 S0100522080003 17621823792 S0100521100009 13122831967 48*12 A 300 500 15%5%15%-5%5%5%5%-5%5%5%*49 前沿报告库是中国新经济产业咨询报告共享平台。行业范围涵盖新一代信息技术、5G、物联网、新能源、新材料、新消费、大健康、大数据、智能制造等新兴领域。为企事业单位、科研院所、投融资机构等提供研究和决策参考。扫一扫免费获取海量报告
展开阅读全文
相关资源
相关搜索
资源标签

copyright@ 2017-2022 报告吧 版权所有
经营许可证编号:宁ICP备17002310号 | 增值电信业务经营许可证编号:宁B2-20200018  | 宁公网安备64010602000642